Next Phase Newsletter

A venture capital arm of a global conglomerate has several global offices including two sites in the US. In 2021, the firm raised a dedicated life science fund to invest in therapeutic and bioprocessing companies with flexibility of entering at different stages of development. The investment size varies depending on the opportunity. The firm is actively seeking new investment opportunities globally.

The firm will make new investments from both traditional funds and their new life science fund. The traditional funds invest in customer-centered health strategies, which may include mobile health IT, digital health, and artificial intelligence applied to healthcare. The new life science fund is interested in therapeutics, particularly gene therapy, ADC technologies, RNA delivery platform technologies, and bioprocessing business that support these strategic areas of interest.

The firm primarily invests in life science companies with a strong and experienced management team. The firm usually takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2012 and headquartered in the US invests in life science, tech, and healthcare companies at Series A and B stages. The firm requires their portfolio companies to have at least one woman in the founding team. Typical check size is USD $1M-3M. The firm is open to investing in global companies, however, the companies need to have some presence in the U.S. as well. The firm usually acts as a co-investor.

The firm’s premise is frontier technology and medical breakthrough. The firm invests in a wide range of life science sectors including therapeutics, diagnostics, and digital health. The firm has invested in hardware, AI in drug discovery, gene editing, and more. The firm is indication-agnostic and will look at companies in all stages of development, though most are earlier.

The firm requires portfolio companies to have at least one woman on the founding team. The firm may not take a board seat on a case-by-case basis as the firm likes to maintain strong relationships with founders and advise in an informal setting.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm based in the US is focused on early-stage health technology investments with a consumer-focus. The firm is looking for companies with solutions that drive consumer engagement and health accountability (these do not have to sell D2C, most of their companies do not). Through the firm’s latest fund, the firm will focus on investing in early-stage, consumer-centric digital health technologies. The firm’s initial investments generally range from $1,000,000 to $5,000,000. The firm is primarily thesis-focused and invests from Seed to Series B, with a focus just at or before the A round.

The firm is seeking digital health companies focused on the empowering consumers to be better stewards of their health and their healthcare expenditures. Accordingly, the firm is not interested in technology that solve problems solely within payers and providers, such as billing, care coordination for hospitals, or EHR platforms. The firm is indication agnostic, though has interest in chronic illnesses, social determinants, behavioral health, and personalized care among others.

The firm does not have set management team requirements. The firm will play a very active role post-investment, traditionally by taking board seats, providing key sales introductions, assisting with scaling, hiring, and providing network support.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.